3SBio Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| 1530.HK | 2696.HK | SMZ1.F | 688266.SS | 688382.SS | 6IB.F | |
|---|---|---|---|---|---|---|
| Market cap | 37.99B | 27.67B | 11.09B | 24.15B | 8.38B | 17.33B |
| P/E (TTM) | 4.1 | 28.8 | 31.2 | 42.6 | — | 124.2 |
| Forward P/E | 11.2 | 28.2 | — | 73.0 | -43.8 | — |
| Price/book | 1.2 | 5.2 | 2.6 | 14.1 | 6.6 | 6.2 |
| Dividend yield | 1.69% | — | 2.90% | — | — | — |
| 1-year change | −51.32% | −19.71% | −23.60% | −10.38% | −48.70% | −1.76% |
| Today | +4.00% | +1.78% | +1.45% | +0.12% | +4.33% | +3.73% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All 1530.HK news ›3SBio and Pfizer’s PD-1×VEGF Bispecific Shows Durable PFS Gains in First-Line NSCLC
Long-term phase 2 data presented at ESMO 2026 show 3SBio’s tivunatamig plus chemotherapy extended progression-free survival vs tislelizumab plus chemotherapy in squamous and non-squamous NSCLC. “For a Phase II study, this is a key positive…
Median PFS Approaches 14 Months! 3SBio's PD-1/VEGF Bispecific Antibody Posts Impressive Data at ESMO 2026
At the selected dose of 10 mg/kg Q3W, the confirmed objective response rate (cORR) for tivunatamig combined with carboplatin + paclitaxel in squamous NSCLC (sq-NSCLC) was 80.7% (vs. 67.7% in the control group), while the cORR for…
3SBio Inc. (OTCMKTS:TRSBF) Sees Significant Drop in Short Interest
3SBio Inc. (OTCMKTS:TRSBF – Get Free Report) was the target of a significant decline in short interest during the month of September. As of September 30th, there was short interest totaling 8,190,396 shares, a decline of 40.6% from the…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- defenseworld.net1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 1 articles, not a forecast.